Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Event, Personnel

Inipharm Appoints Chuhan Chung, M.D, as Chief Medical Officer to Advance HSD17B13 Program into the Clinic


Inipharm, a biopharmaceutical company focused on discovering and developing therapies for severe liver diseases, today announced that it has appointed Chuhan Chung, M.D., as the company's chief medical officer. Inipharm will also be presenting preclinical data on one of its small molecule HSD17B13 inhibitors at the International Liver Congresstm 2022, occurring in London.

Dr. Chung joins Inipharm after serving as executive director and global development lead at Gilead Sciences, where he was responsible for clinical studies in NASH and primary sclerosing cholangitis. Before joining Gilead, Dr. Chung served as associate professor at the Yale University School of Medicine, Section of Gastroenterology & Hepatology where he maintained an independently funded lab focused on conducting translational research in liver disease.

"Multiple clinical datasets have demonstrated that inactive forms of HSD17B13 are associated with protection against severe liver disease," said Dr. Chung. "This provides a strong rationale for targeting HSD17B13, and I look forward to working with our leadership team and scientific advisors to develop and execute clinical development plans for this exciting program."

Inipharm's presentation at the International Liver Congress, entitled "Metabolomic changes in NASH phenotype liver-on-a-chip caused by INI-678, a small molecule HSD17B13 inhibitor, supports a role for HSD17B13 in inflammation and fibrosis," will focus on the impact of inhibiting HSD17B13 with a well characterized inhibitor, INI-678, in a NASH phenotype "liver-on-chip" system containing primary human liver cells. In this model, treatment with INI-678 resulted in improvements in markers of fibrosis which were accompanied by decreased levels of bile acids, stabilized choline and decreased hexose.

"The metabolomics in a primary human cell system treated with a potent, selective inhibitor of HSD17B13 point to the key role that this target plays in pathways that are important to liver health," said Heather Hsu, Ph.D., chief scientific officer of Inipharm. "The overall findings are consistent with the liver protective effects observed in human carriers of inactive HSD17B13 alleles."

About Inipharm

Inipharm is a biopharmaceutical company focused on discovering and developing therapies for severe liver diseases. Inipharm's lead programs are focused on the highly validated genetic target, HSD17B13. Extensive, consistent evidence that genetic variants in expression of HSD17B13 are associated with significantly lower rates and severity of multiple liver diseases. Building on these novel insights into the biologic activity of HSD17B13, Inipharm is advancing a pipeline of small-molecule therapies that target the activity of this protein.


These press releases may also interest you

at 05:10
Neurology Devices: Global Markets is basically a detailed study or report about the worldwide market for medical tools used in treating neurological conditions. These devices could be anything from equipment that helps stimulate the nervous system to...

at 05:04
Sirnaomics Ltd. (the "Company"; together with its subsidiaries, "Sirnaomics" or the "Group"; stock code: 2257), a leading biopharmaceutical company engaged in the discovery and development of advanced RNAi therapeutics, has announced its audited...

at 04:28
GymNation, the homegrown UAE fitness brand, has today announced that due to unprecedented growth, it is reaching capacity across its 12 UAE gym locations and diversifying into a new market, brewing up a storm with the launch of its first-ever branded...

at 04:00
Cancer spreads from its primary tumor to other parts of the body via blood or the lymphatic system in a process termed 'metastasis'. This usually represents an advanced stage in the disease's progression and tends to be fatal. Therefore, preventing...

at 03:30
Vicore Pharma Holding (STO:VICO)Sessions at ATS to include an oral late-breaking presentation of the final results from the Phase 2a AIR trial of buloxibutid (C21) in IPFAdditional presentations include preclinical and translational data reflecting...

at 03:13
Orexo's Annual and Sustainability Report for 2023 has been published and can be downloaded at, www.orexo.com. The Swedish version of the Report is also available on the company's website in European Single Electronic Format (ESEF). A PDF version is...



News published on and distributed by: